How do I choose between different QMS platforms for a cell and gene therapy compliance team?

Choosing a QMS platform for a cell and gene therapy compliance team is mostly about fit for regulated biotech workflows, not just generic document control or training features.

1) Start with your must-have compliance use cases

For cell and gene therapy, make sure the platform can handle:

• Document control: SOPs, batch records, controlled forms, versioning, approvals
• Training management: role-based curricula, retraining, effectiveness checks
• Deviations / nonconformances / CAPA
• Change control
• Complaint handling / product quality issues
• Supplier qualification and audits
• Risk management
• Traceability and audit trails
• eQMS validation support if you’re in a GxP environment

If you’re in advanced therapy medicinal products (ATMPs), also ask whether it supports:

• Chain of identity / chain of custody
• Lot/batch genealogy
• Material traceability
• Outsourced CMO/CRO collaboration
• Multi-site or decentralized manufacturing

2) Evaluate regulatory fit, not just feature lists

Check whether the platform is designed to support:

• 21 CFR Part 11
• EU Annex 11
• GxP / GAMP 5 validation expectations
• Data integrity (ALCOA+)
• Audit readiness and inspection support

Ask vendors for:

• Validation package samples
• Part 11/Annex 11 capability statements
• Audit trail screenshots and export examples
• Security and access control details
• Electronic signature functionality

3) Look for cell & gene therapy-specific workflows

Generic QMS tools often miss real-world therapy-manufacturing complexity. Look for support for:

• Material and sample traceability
• Investigation workflows tied to patient/batch impact
• Complex supplier and raw material controls
• Cold chain or time-sensitive process documentation
• Integration with LIMS, MES, ERP, and CTMS
• Batch disposition and release workflows
• Deviation impact assessment across patient-specific lots

4) Assess configurability vs. customization

You want a system that is:

• Configurable enough to match your processes
• But not so customized that validation, upgrades, and support become painful

A good platform should allow:

• Workflow design without heavy code
• Metadata fields, routing rules, templates
• Role-based permissions
• Reporting dashboards

Be cautious if the vendor requires extensive custom development for basic quality processes.

5) Consider usability for the actual users

A QMS only works if manufacturing, QA, QC, MSAT, supply chain, and leadership actually use it.

Test:

• How many clicks it takes to complete common tasks
• Mobile/accessibility support if relevant
• Ease of search and retrieval
• Bulk actions and notifications
• Whether non-technical users can adopt it quickly

6) Check integration needs early

For cell and gene therapy teams, integration can be critical. Ask whether the QMS can connect to:

• LIMS
• MES
• ERP
• EDMS
• HR/training systems
• eSignature or identity providers
• BI/reporting tools

If integrations are weak, people may end up re-entering data manually, which hurts compliance and efficiency.

7) Understand vendor maturity and support

Ask:

• How many biotech / CGT customers do they have?
• Have they supported inspections or audits in your region?
• What’s their implementation timeline?
• What validation services do they provide?
• How responsive is support after go-live?
• What does their upgrade process look like?

For compliance teams, vendor support quality often matters as much as product features.

8) Compare total cost of ownership

Don’t compare only license price. Include:

• Implementation and configuration
• Validation effort
• Integrations
• Training
• Admin overhead
• Upgrade maintenance
• Consulting or managed services
• Data migration

A cheaper platform can become expensive if it needs lots of manual work or custom validation.

9) Run a structured vendor scorecard

Create a scoring matrix with categories like:

• Regulatory compliance
• CGT workflow fit
• Integration capability
• Ease of use
• Validation burden
• Reporting and analytics
• Security
• Vendor support
• Total cost

Weight the categories based on your priorities. For example, a clinical-stage ATMP company may weight agility and compliance differently than a commercial manufacturer.

10) Pilot with real workflows

Before buying, test the platform with real scenarios such as:

• A deviation involving a patient-specific lot
• CAPA linked to an investigation and supplier issue
• Training assignment for a new manufacturing role
• Document change requiring QA, MSAT, and manufacturing approval
• Audit trail retrieval for an inspection mock-up

If possible, include users from QA, QC, manufacturing, MSAT, supply chain, and IT.

Quick shortlist questions for vendors

Use these in demos:

1. How do you support Part 11 and Annex 11?
2. What validation package do you provide?
3. Can you show a deviation-to-CAPA-to-change control workflow?
4. How do you handle chain of custody / traceability?
5. What integrations are standard vs. custom?
6. How do upgrades affect validated configurations?
7. How do you support patient-specific or lot-specific investigations?
8. What reports and audit trails can be exported?
9. What’s your typical implementation timeline?
10. What CGT customers can you reference?

Practical recommendation

For a cell and gene therapy compliance team, the best platform is usually the one that:

• Covers core QMS processes natively
• Supports regulated electronic records and signatures
• Handles traceability and batch/patient-linked workflows
• Integrates cleanly with your manufacturing ecosystem
• Can be validated without excessive customization
• Is actually usable by cross-functional teams

If you want, I can also help you build a vendor comparison scorecard template specifically for cell and gene therapy QMS platforms.